

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

PL9824

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

To be assigned 09/763788

INTERNATIONAL APPLICATION NO.  
PCT/SE99/01484INTERNATIONAL FILING DATE  
27 August 1999PRIORITY DATE CLAIMED  
28 August 1998

## TITLE OF INVENTION

Composite Material and Its Use

## APPLICANT(S) FOR DO/EO/US

Per-Olof Larsson and Per-Erik Gustavsson

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of item/s concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☒ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

## Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

Copy of the International Application as published by the International Bureau

Return Postcard

Copy of this transmittal letter for charging purposes

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/763788

INTERNATIONAL APPLICATION NO

PCT/SE99/01484

ATTORNEY'S DOCKET NUMBER

PL9824

21. The following fees are submitted..

CALCULATIONS PTO USE ONLY

**BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :**

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1,000.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =****\$860.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	30 - 20 =	10	x \$18.00	<b>\$180.00</b>
Independent claims	2 - 3 =	0	x \$80.00	<b>\$0.00</b>
Multiple Dependent Claims (check if applicable).				<input type="checkbox"/> <b>\$0.00</b>

**TOTAL OF ABOVE CALCULATIONS =****\$1,040.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).

☐**\$0.00****SUBTOTAL =****\$1,040.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

☐**\$0.00****TOTAL NATIONAL FEE =****\$1,040.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

☐**\$0.00****TOTAL FEES ENCLOSED =****\$1,040.00**

Amount to be:  
refunded \$  
charged \$


- ☐ A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.
- ☒ Please charge my Deposit Account No. **500-588** in the amount of **\$1,040.00** to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **500-588** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

**Royal N. Ronning, Jr.**  
**Amersham Pharmacia Biotech, Inc.**  
**800 Centennial Avenue**  
**Piscataway, New Jersey 08855-1327**  
**USA**

(732) 457-8423

  
SIGNATURE

**Royal N. Ronning, Jr.**

NAME

**32,529**

REGISTRATION NUMBER

**February 23, 2001**

DATE

PL9824

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: P. Larsson, et al.                      Group Art Unit:              To be assigned  
Serial Number: To be assigned                      Examiner:                      To be assigned  
Filing Date:              February 23, 2001  
Title:                      Composite Material and Its Use

**FIRST PRELIMINARY AMENDMENT**

Honorable Assistant Commissioner of Patents and Trademarks  
Washington, D.C. 20234

Sir:

Please consider the following amendments and remarks in connection with the prosecution of the captioned application, which claims priority to PCT/SE99/01484 filed August 27, 1999.

**IN THE CLAIMS**

In Claim 1, line 1, please insert – A – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 2, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 3, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 3, line 1, please delete “any of claims 1-2” and substitute – Claim 1 – therefor.

In Claim 4, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 4, line 1, please delete “any of claims 1-2” and substitute – Claim 1 – therefor.

In Claim 5, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 5, line 1, please delete “any of claims 1-2” and substitute – Claim 1 – therefor.

In Claim 6, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 6, line 1, please delete “any of claims 1-5” and substitute – Claim 1 – therefor.

In Claim 7, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 8, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 9, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 10, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 10, line 1, please delete “any of claims 6-9” and substitute – Claim 6 – therefor.

In Claim 11, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 11, line 1, please delete “any of claims 1-10” and substitute – Claim 1 – therefor.

In Claim 12, line 1, please insert – The – at the beginning of the claim and please delete “Composite” and substitute – composite – therefor.

In Claim 12, line 1, please delete “any of claims 1-11” and substitute – Claim 1 – therefor.

In Claim 13, line 1, please delete “any of claims 1-11 ” and substitute – Claim 1 – therefor.

**Please add the following new Claims as follows:**

14. The use according to Claim 13, characterized in that the use is for chemical synthesis of a polymer on the composite material, such as of an oligonucleotide or an oligopeptide.

15. The use according to Claim 13, characterized in that the use is for enzymatic/ catalytic reactions which are performed in a bio-reactor with the enzyme or catalyst bound to the composite material.

16. The use according to Claim 13, characterized in that the use is for culturing of cells wherein the cells are cultured on the composite material.
17. A method for the chemical synthesis of a polymer such as an oligonucleotide or an oligopeptide on a solid phase, characterized in that the solid phase is the composite material which is defined in Claim 1.
18. A method for performing enzymatic/catalytic reactions in a bio-reactor, characterized in that the enzyme and/or catalyst used is bound to a composite material which is defined in Claim 1.
19. A method for culturing cells, characterized in that the cells are cultured on the composite material which is defined in Claim 1.
20. A separation method comprising that a solution containing substances that are to be separated are passed through a bed containing a separation material, said method being based on affinity between a substance to be separated and a ligand bound to the separation material or on differences in shape or in molecular weights of the substances to be separated,  
characterized in that said material is a composite material comprising two or more components of which one is super-porous polysaccharide (main component) which outside the superpores contains a gel phase with micro-pores and the other component(s) (secondary component(s)) are different from the main component.
21. The separation method of Claim 20, characterized in that the main component is in the form of discrete particles or of a continuous structure.
22. The separation method of Claim 20, characterized in that at least one of the secondary components is within the super-pores of the main component.
23. The separation method of Claim 20, characterized in that at least one of the secondary components is present in both the super-pores and in the gel phase of the main component.
24. The method of Claim 20, characterized in that the affinity ligand is selected amongst ion exchange groups, amphoteric groups, chelating groups, bio-affine groups, groups which can be used in covalent chromatography, groups which gives  $\pi$ - $\pi$ - interaction, groups which can be used during hydrophobic interaction chromatography, groups which give thiophilic interactions, or affinity binding inorganic materials which can be present as a secondary component, such as hydroxyapatite.
25. The separation method of Claim 20, characterized in that said composite material is in the form of particles.

26. The separation method of Claim 25, characterized in that said particles are in the form of a packed bed or a fluidized bed.
27. The separation method of Claim 20, characterized in that said composite material is in the form of a monolith.
28. The separation method of Claim 20, characterized in that the composite material carries an affinity ligand and that the substance after the solution has passed through the bed is desorbed from the composite material by the use of a solution containing a desorbing agent.
29. The separation method of Claim 28, characterized in that the desorbing agent gives an increased ionic strength, a change in pH or competes with the bonding between the substance and the affinity ligand.
30. The separation method of Claim 20, characterized in that the combination of electroelution of a bound substance from the composite material with a composite material comprising a monolithic electrically conducting secondary component is excluded.


#### REMARKS

Claims 1-13 were pending in the captioned application. Applicants have amended claims 3, 4, 5, 6, 10, 11, 12, and 13 to more fully conform with U.S. practice and to delete multiple dependencies. Applicants have added new Claims 14-30.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry.

Applicants believe that the claims, as amended, are an allowable form, and earnestly solicit the allowance of Claims 1-30.

Respectfully submitted,



Royal N. Ronning, Jr. 32,529  
Attorney for Applicants

Amersham Pharmacia Biotech, Inc.  
800 Centennial Avenue  
P. O. Box 1327  
Piscataway, NJ 08855-1327  
Tel: (732) 457-8423  
Fax: (732) 457-8463

Composite material and its use

## Field of the invention

- 5 The invention relates to a composite material in which is comprised super-porous polysaccharide material of the type which has been previously described in WO-A-9319115 (US-A-5,723,601).

10 Porous polysaccharide material contains two types of pores. Partly pores with a small diameter (often less than 0.05 micrometers, micro-pores) where mass transportation occurs by diffusion when a liquid is transported through the material. Partly large pores - super-pores - in which mass transportation can take place through a convective flow when the pores are open. The part of the material that lies outside the super-pores is called the gel phase and consequently contains the micro-pores.

15

We have described super-porous agarose matrices in a series of articles. See Gustavsson et al., J. Chromatog. A 734 (1996) 231-240, Gustavsson et al., J. Chromatog. A 776 (1997) 197-203, Gustavsson et al., J. Chromatog. A 795 (1998) 199-210.

- 20 It is known in the prior art to place super-porous agarose in the pores of highly porous electrically conductive material (reticulated vitreous carbon, RVC) in order to increase the material's capacity to carry affinity-bonding ligands. See Khayyami, Thesis "Biosensors and chromatographic supports based on new combinations of conductive material", Lund University, Lund (1996). Their fields of use have been as biosensors or as chromatography
- 25 adsorbents that should be able to be electroeluted. Agarose alone is unusable in the current type of biosensors and for electroelution. By electroelution is meant that a bonding ligand is oxidised/reduced in an electrochemical way to be non-bonding so that elution is made possible.

- 30 Unfortunately it has not yet been possible to completely use super-porous polysaccharide material in the way that would be desirable. Consequently one often wishes that the matrices characteristics would be better with respect to physical stability (pressure resistance), separation characteristics with respect to discriminating between substances with different molecular weights and geometric shape, stability of the affinity ligands which are linked to a
- 35 super-porous matrix etc. It can especially be mentioned that certain applications, especially those that require matrices in particular shapes, require a density that more or less strongly deviates from 1 g/cm<sup>3</sup>.

Previous publications, such as WO-A-9319115 (US-A-5,723,601), have been relatively scarce about deficiencies of super-porous polysaccharide material and how to overcome these deficiencies. To our knowledge previous publications, such as WPI/Derwent AN 95-158047  
5 relating to composite polysaccharide material do not discuss the presence of super-pores therein.

We have now discovered that it is very easy to manufacture composite materials in which a super-porous polysaccharide matrix is included as the main component of the material and  
10 that this can offer advantages with respect to the above-mentioned deficiencies of prior art super-porous polysaccharides.

### **The invention**

15 A first aspect of the invention is a composite material that comprises two or more components. The composite is characterised in that one of the component is a super-porous polysaccharide material (main component). Other components are called secondary components (secondary components 1, 2, 3 etc). That the composite material of the invention contains an electrically conducting monolithic secondary component which is intended to  
20 connect or which is connected between two electrodes is not part of this aspect of the invention.

Another aspect of the invention is the use of the composite during separation, cell culturing, chemical synthesis on solid phase, and the performance of enzymatic/catalytic reactions  
25 where the enzyme is linked to the composite material in accordance with the invention (the method aspect of the invention).

The composite material can be in the form of fibres, balls (beads, particles), or a monolith. As an example of a monolith can be mentioned membranes or a cast continuous chromatographic  
30 bed. With matrices in the shape of balls one often speaks of sizes in the intervals of 0.1-1000  $\mu\text{m}$ , such as 1-1000  $\mu\text{m}$  or 5-500 $\mu\text{m}$ .

### **The main component (super-porous polysaccharide material)**

35 Typically super-porous polysaccharide materials are often manufactured starting from agar, agarose, alginate, dextran, carageenan, chitosan, cellulose or starch. Which material is chosen in the actual case is often determined by the characteristics that one wishes that the final



product shall have with respect to pore size, charge, stability in different media, cost etc. The super-porous polysaccharide material may be a homogeneous mixture of different polysaccharides forming the gel phase of the material. Super-porous polysaccharide material for use in the invention can be made in the same way as stated in WO-A-9319115.

5

The term super-pores means that a flow which can give convective mass transport should be able to be applied through the pores. This means as a rule that there shall be pores with diameters which are in the interval of 0.5-1000  $\mu\text{m}$ , with a preferred interval of between 1-1000  $\mu\text{m}$ . For matrices in the shape of particles which are packed to form a bed there is  
10 furthermore a condition that the relationship between super-pore diameter and the particle diameter is in the interval of 0.01-0.3, with a preference for 0.05-0.2.

The amount of the main component in the composite material of the invention can vary within extremely wide limits. Based on dry weight the amount of main component can consequently  
15 vary from just over 0% to just under 100%, such as 0.01-99.99% (w/w). Based on volume and measured on composite material saturated with water the main component can form 5-99.99%, for example 50-99% (v/v).

### Secondary components

20

The secondary components of the composite material can be a) particles which are enveloped in the main components gel phase and/or in the super-pores, or b) a continuous phase in the super-pores, or c) polymer chains which are homogeneously mixed in the gel phase with the main component's polysaccharide. In the variant a) there are particles which are coated with  
25 super-porous polysaccharide material. In the variant b) there is a macro-porous secondary component completely surrounding the super-porous polysaccharide material.

The secondary components differ from the main components with respect to at least one characteristic. The secondary components can be selected from different organic and  
30 inorganic material. They can be polymers with a completely synthetic origin or be based on so-called biopolymers, for example polysaccharides of the same or different types than those that are current as the main component. They can be derivituted to carry different groups that can be used during the use of the composite material of the invention. In the composite material of the invention a secondary component can be present as a solid substance or fluid  
35 and is as a rule insoluble in water (in the absence of additives that change its solubility).

A secondary component can be porous. If a secondary component is porous then its average pore diameter (in the composite material) can be larger than or smaller than or the same as the average pore diameter of the micro-pores in the main component's gel phase.

- 5 The secondary components can have a density that more or less greatly differs from  $1 \text{ g/cm}^3$ .

As examples of the great variability which applies to the secondary components reference can be made to WO-A-9200799. One can also mention the following functions that can be introduced into the composite via a secondary component:

10

- density, for example particles with high or low density.
  - magnetic attraction, for example particles of magnetite.
  - affinity functions, described more closely in the following section.
  - mechanical stability, for example polymers, particles or continuous structures such as
- 15 reticulated vitreous carbon (RVC).
- thermal stability, for example polymers or other reagents which stabilise the melting point of main component 1.
  - photo-chemical stability, for example the addition of coloured particles.
  - microbial stability, for example polymers which prevent the entry of micro-
- 20 organisms/hydrolytic enzymes.
- electrical conductivity, for example electrically conductive polymers, in particulate or monolithic form. Particularly the case that an electrically conducting secondary component is monolithic and connected between two electrodes is not included in the composite in accordance with the invention.
- 25 • pore size modification, for example polymer networks which reduce the size of the super-pores in the main component.
- Heat conductivity, for example particles or heat conducting structures such as reticulated vitreous carbon, which can rapidly remove or add heat.
  - Variable composite material characteristics, for example via so-called smart polymers.
- 30 Smart polymers are polymers which dramatically can change their characteristics as a result of an outside stimulus. An example is to introduce a thermo-responsive smart polymer into the super-pores and thereby make these variably permeable via small temperature changes.

35 **Derivatized forms of the composite material of the invention**

The composite material of the invention can be provided with so called affinity ligands which are bonded to the main components and/or to one or more of the secondary components of the composite material. As examples of affinity ligands can be mentioned anion- or cation exchange groups, amphiphilic groups, chelating groups, bio-affine groups, groups which can be used in covalent chromatography, groups which give  $\pi$ - $\pi$ -interaction, groups which can be used during hydrophobic interaction chromatography, groups which give thiophilic interactions etc. A special kind is affinity ligands are present on affinity bonding inorganic material for example hydroxyapatite, etc.

- 10 The different components in the composite material of the invention can, when they are based on polymers, be cross-linked in a way that is in itself known.

Cross-linking and the introduction of affinity ligands can take place in the finished composite material or in the respective main component before the composite material is made.

15

It is evident above that the cross-linking structures, the introduced ligands and other binding structures which occur through chemical derivatisation of a base material are not called secondary components in connection with the invention.

## 20 **Manufacturing of the composite material of the invention**

The composite material in accordance with the invention can be made through first making a solution of the polysaccharide which is to be the main component in the finished composite material and suspending particles of the secondary components 1, 2, 3 etc. in the solution and thereafter proceeding as is known from the manufacturing of super-porous polysaccharide material in accordance with WO-A-9319115. It is essential to make sure that the secondary components 1, 2, 3 etc. do not sediment out during the manufacturing process.

A composite in accordance with the invention can even be manufactured through a) starting from super-porous polysaccharide material (the main component) manufactured in accordance with WO-A-9319115 and introducing secondary components 1, 2, 3 etc. into the super-pores, or b) starting from a macro-porous secondary component and manufacturing the super-porous polysaccharide material (main component) in the pores of the macro-porous secondary component.

35

## **The field of use of the invention**

The composite material in accordance with the invention has potentially the same area of use as other previously known porous materials. Some actual areas are, amongst others, in connection with separations, cell-culturing, bio-reactors and chemical synthesis. Examples of actual bio-reactors are, amongst others, enzyme reactors and other reactors where the catalyst is bound to a matrix. Examples of actual chemical syntheses are the synthesis of polymer in the solid phase, such as oligopeptides and oligonucleotides. During cell culturing the cells can be grown on the composite material of the invention.

By separation is meant first of all separations based on the affinity between the substance which is to be separated and a structure (ligand) on the matrix of the invention or based on differences in geometric shape and molecular weight between different substances. These separations can take place in the form of chromatographic or stepwise methods or methods which are based upon membrane technology. According to the first variation a solution containing the substances which are to be separated from each other is passed through a bed which contains the composite material of the invention. The bed can be in the shape of a porous monolithic matrix, packed particles or a so-called expanded bed (see WO-A-9218237). During stepwise methods the composite material of the invention is in the shape of particles which are suspended in a solution which contains the substances which are to be separated from each other. Elution/desorption/freeing of the bonded substances can then, amongst others, take place through the addition of solutions that interrupt the bonds between the ligand and the bonded substance. Depending on the type of ligand the solution can contain desorbing agents that give an increased ion strength, a changed pH or which directly compete with the bonding between the ligand and the bonded substance. Electroelution which uses a composite material with a monolithic electrically conducting secondary-component which is connected between two electrodes in combination with electroelution is not included in the method aspect of the invention.

In principle, beds constructed in a similar way can be used during cell-culture, chemical synthesis and in bio-reactors.

The invention is defined furthermore by the accompanying claims and will now be illustrated with a number of non-limiting examples.

#### EXPERIMENTAL PART

In this experiment we have started from the examples which were given in the International Patent Application WO-A-9319115.

**Example 1. Monolithic composite material. Continuous super-porous membrane with filler in the gel-phase.**

- 5 • 10 ml of a 6% agarose solution was made in accordance with example 1 in WO-A-9319115 (solution A).
- 10 ml cyclohexane + 1 ml Tween-80 manufactured in accordance with example 1 in WO-A- 9319115 (solution B)
- 10 ml filler was heated to 60°C (solution C).

10

Solution A and solution C were combined while being stirred at 60°C. Thereafter solution B was added while being stirred (1000 rpm) at 60°C in order to obtain emulsion 1 in the same way as described in WO-A-9319115. From emulsion 1 super-porous continuous composite membranes were made in accordance with example 4 in WO-A-9319115.

15

The following alternative filler was used:

- a. Anion exchanger, AG 1X-8 minus 400 mesh (Bio-Rad Laboratories, U.S.A.). The resulting composite material was shown to function through the determination of break-through curves for ATP.
- 20 b. Silica material LiChroprep Si 100, 40-63 µm (E. Merck Darmstadt, Germany).
- c. Agarose spheres (6% Agarose 25-75 µm) derivatised with Cibacron-blue. These agarose spheres were manufactured in accordance with Gustavsson and Larsson, J. Chromatography A, 734 (1996) 231-240, but with a stirring speed of 1500 rpm.
- d. Graphite, powder synthetic, 1-2 µm (Aldrich, U.S.A.). In this case 20 ml of 6% agarose
- 25 solution and 2.5 ml of graphite powder were used.

**Example 2. Composite material in the shape of spheres/beads. Super-porous agarose beads having super-pores in which a low percentage agarose solution was cast.**

30 The following super-porous agarose spheres were manufactured in accordance with WO-A-9319115 using as starting material:

1. Agarose content 6%, particle sizes 300-500 µm, super-pore volume 40%, super-pore diameter 30 µm.
  2. Agarose content 6%, particle sizes 106-180 µm, super-pore volume 40%, super-pore
- 35 diameter 30 µm.

These super-porous agarose spheres were used in order to manufacture composite material through filling the super-pores with 0.5% agarose in accordance with the following:

- The interstitial water of 20 ml sedimented super-porous agarose beads was filtrated off in a Büchner filter and the super porous agarose beads transferred to an E-flask. The E-flask was heated to 50°C in a thermostat controlled water bath (gel A).
- 0.5 g agarose (low gelling temperature, Sigma A-4018) was added to 100 ml distilled water and heated to 95-100°C in a microwave oven. The agarose solution was tempered down to 50°C in a thermostat controlled water bath (solution B).
- Solution B was added to gel A and placed in a vibrating water bath (50°C) for 22 hours (suspension C).
- 200 ml of cyclohexane + 5.6 g Span-85 (Fluka, Buchs, Switzerland) were tempered to 50°C in a stirred tank reactor. Suspension C was added to the tank reactor (50°C) while being stirred (1500 rpm). After 1 minute the temperature in the tank reactor was lowered to 5°C with continued stirring (1500 rpm).

In the final stage the desired composite material was formed, that is to say super-porous agarose beads with 0.5% agarose in the super-pores and normal agarose beads with an agarose content of 0.5%. The latter could be easily separated through sedimentation.

#### Functional testing of the agarose composite beads (6% - 0.5% agarose):

The above manufactured composite beads were packed in chromatography columns and used for gel filtering. These composite beads could separate latex particles (0.5 µm) and Blue Dextran MW 2 000 000, which were eluted at the same time during gel filtering experiments with columns packed with normal agarose beads or super-porous agarose beads. The explanation is that Blue Dextran 2 000 000 has access to the super-pore volume while the latex particles does not have access to the volume because they are excluded from 0.5% agarose pores. This type of composite bead can be used for increasing the separation area for DNA during gel filtration.

#### Example 3. Composite material in the shape of beads. Super-porous agarose/polyacrylamide beads.

**Comment.** In this composite the gel phase itself consist of cross-linked polyacrylamide + agarose.

- 0.0625 g N,N'-methylene-bis-acrylamide was dissolved in 25 ml 10% acrylamide. The solution was vacuum-degassed and tempered to 60°C (solution A).
- 2.4 g agarose was dissolved in 30 ml vacuum-degassed water and heated in a microwave oven to 95-100°C. The agarose solution was tempered to 60°C in a stirred tank reactor (solution B).
- 25 ml cyclohexane with 1.5 ml Tween-80 was degassed with nitrogen and tempered to 60°C (solution C).
- 150 ml cyclohexane with 8.4 g Span 85 was degassed with nitrogen and tempered to 60°C (solution D).

10

The solution A was mixed into the solution B while being stirred (500 rpm, 15 min) at 60°C (solution E). 0.05 ml TEMED and 30 mg ammonium persulphate was separately dissolved in a small quantity of degassed water and added to the solution E while being stirred (500 rpm, 2 min). The solution C was added to the solution E and emulsified at 100 rpm for 0.5 min. The solution D was added to solution E and emulsified at 500 rpm for 1 minute, thereafter being cooled to 25°C. Stirring continued for 30 minutes at 500 rpm.

The gel beads obtained were washed as described in WO-A-9319115.

#### 20 **Example 4. Monolithic composite material based on a monolithic mechanical support matrix and super-porous polysaccharide matrices.**

Reticulated vitreous carbon was used (RVC; Duocell, Energy Research and Generation, Oakland, CA, USA) as a mechanical support matrix.

25

The emulsion 1 in accordance with example 1 in WO-A-9319115 was placed in a thermostat controlled glass column (50°C) in which a matrix of RVC was placed. The column was lowered into a cooling bath wherein the agarose phase solidified. The resulting composite material was trimmed at its ends and washed free from organic solvent. The function of the material was tested in comparative chromatographic studies with BSA as the chromatographed molecule.

30

#### **Example 5. Monolithic composite material based on super-porous agarose and yeast cells.**

35

A composite was manufactured in accordance with example 1. 10 ml of 50% content yeast suspension (bakers yeast) was used as a secondary component. The finished composite was investigated and found to have enzymatic activity (alcohol dehydrogenase activity).

**5 Example 6. Composite material in the shape of beads. Ion-exchange matrix.**

- 10 ml 2-6% agarose solution was made (60°C). To the solution was added a sodium alginate solution (4% w/v) to a final concentration of 0.25-1% (w/v) (solution A).
- 10 ml cyclohexane + 0.6 ml Tween-80 were heated to 60°C (solution B).
- 10 • 50 ml cyclohexane + 2 g Span 85 were heated to 60°C (solution C).
- The solution B was added to solution A and stirred at 1000 rpm for 2 minutes at 60°C (solution D).

Super-porous alginate-agarose beads were manufactured in accordance with the following two methods:

- 15 Method 1: Solution D was added to solution C in a stirred reactor tank (600 rpm, 60°C). The agarose was allowed to solidify after 1 minute by cooling the reactor tank to 25°C. The alginate in the agarose phase was polymerised through a  $\text{CaCl}_2$ -water solution (small volume) being added to the reactor and while being stirred just before or just after the cooling.

20

- Method 2: The solution D was added drop-wise with a Pasteur pipette down in a heated beaker (60°C). The beaker contained two phases. The top phase consisted of solution C. The bottom phase consisted of 1.5%  $\text{CaCl}_2$  in water. The beaker was stirred with a magnetic stirrer without the phases being mixed. The composite
- 25 material made was washed with water, ethanol-water (1:1) and water.

**Example 7. Monolithic agarose-hydroxyl apatite composite material.**

- 25 ml sedimented hydroxyl apatite in 1 mM sodium phosphate buffer went through a series of
- 30 sedimentations under which the smallest particles (in total 9 ml of the sedimented hydroxyl apatite) were removed. 5 ml sedimented volume of the hydroxyl apatite which was left (1mM sodium phosphate buffer pH 6.8) was heated with a thermostat control to 60°C. 20 ml of an agarose solution (8% w/v) was made through heating for one minute a suspension of agarose in water to 95-100°C in a microwave oven. During the heating the agarose powder was
- 35 maintained well suspended through occasional shaking. The agarose solution was heated to 60°C using a thermostat control whereafter 15 ml was added to the thermostat temperature-controlled hydroxyl apatite. The solution with the agarose-hydroxyl apatite was stirred then at



- 1000 revolutions per minute in a thermostat controlled water bath (60°C). After 5 minutes a mixture of 0.75 ml Tween-80 and 10 ml cyclohexane (60°C was added). The mixture was emulsified through stirring at 1000 revolutions per minute for two minutes. The emulsion was poured into glass columns (16 mm inside diameter) which were held at a thermostat
- 5 controlled temperature of 60°C in a water bath. After 30 seconds the glass columns were transferred to an ice-bath in order to be cooled. The insoluble continuous beds (containing hydroxyl apatite) which were obtained were trimmed to a length of 1.4 cm and placed in glass columns (16 mm ID) which were equipped with flow adapters. The organic phase in the super-pores was removed through pumping sodium phosphate buffer pH 6.8, ethanol-1 mM
- 10 sodium phosphate buffer pH 6.8 (50:50 v/v) and finally sodium phosphate buffer pH 6.8 through the column. The composite bed was stored at 4°C until it was used.

- The columns were then connected to an HPLC-system (Amersham Pharmacia Biotech AB; Uppsala, Sweden) including pumps, injection valves, UV-Vis detector and printer. Separation
- 15 of three model proteins (lysozyme, cytochrome c and bovine serum albumine) were then studied with three different flow speeds (15 cm/h, 30 cm/h, 60 cm/h). The composite bed had a super-pore/interstitial porosity of 33% (defined by the method of production) and a super-pore/interstitial average pore diameter of 30 µm (measured through observation in a microscope).

with coloured amendments

12

## CLAIMS

1. Composite material, characterized in that it comprises two or more components of which one is super-porous polysaccharide (main component) which outside the superpores  
5 contains a gel phase with micro-pores and the other component(s) (secondary component(s)) are different from the main component with exception of the case that the composite contains an electrically monolithic secondary component which is intended to be, or is, connected between two electrodes.
- 10 2. Composite material according to claim 1, characterized in that the main component is in the shape of discrete particles or a continuous structure.
3. Composite material according to any of claims 1-2, characterized in that at least one of the secondary components is outside the super-pores but inside the main component's gel  
15 phase.
4. Composite material according to any of claims 1-2, characterized in that at least one of the secondary components is in the super-pores of the main components.
- 20 5. Composite material according to any of claims 1-2, characterized in that at least one of the secondary components is ~~found~~ present in both the super-pores and in the gel phase of the main component.
6. Composite according to any of claims 1-5, characterized in that it has at least one  
25 affinity ligand.
7. Composite material according to claim 6, characterized in that the respective affinity ligand is linked to the main component and/or to one or more secondary components.
- 30 8. Composite material according to claim 6, characterized in that at least one of the affinity ligands is linked to the main component.
9. Composite material according to claim 6, characterized in that at least one of the affinity ligands is connected to one of the secondary components.

35

with coloured amendments

13

10. Composite material according to any of claims 6-9, characterized in that said at least one of the affinity ligands is an ion exchange group, amphoteric group, chelating group, bioaffine group, a group which can be used in covalent chromatography, a group which gives  $\pi$ - $\pi$ -interaction, a group which can be used during hydrophobic interactions chromatography, a group which give thiophilic interactions, or an affinity binding inorganic material which is a secondary component, such as hydroxyapatite, etc.
11. Composite material according to any of claims 1-10, characterized in that the secondary components are porous with average pore diameters which are greater than the average pore diameters in the gel phase of the main component.
12. Composite material according to any of claims 1-11, characterized in that it is in the shape of fibres, beads, or a monolith, such as a membrane or a bed.
13. The use of the composite material according to any of claims 1-11 in separations, the culturing of cells, chemical synthesis, enzymatic/catalytic reactions.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION</b> (37 CFR 1.63)	<b>Attorney Docket Number</b>	PL9824
	<b>First Named Inventor</b>	Larsson
	<b>COMPLETE IF KNOWN</b>	
	<b>Application Number</b>	09 / 763,788
	<b>Filing Date</b>	23-Feb-2001
	<b>Group Art Unit</b>	To be assigned
<input type="checkbox"/> Declaration Submitted with Initial Filing	<b>OR</b>	<input checked="" type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)
<b>Examiner Name</b>		To be assigned

**As a below named inventor, I hereby declare that:**

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**Composite Material and Its Use**

the specification of which (Title of the Invention)

☐ is attached hereto

**OR**

☒ was filed on (MM/DD/YYYY) **02/23/2001** as United States Application Number or PCT International Application Number **09/763,788** and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
9802882-2	Sweden	08/28/1998	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

☐ Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement. This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/SE99/01484	08/27/1999	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/01

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact with the Patent and Trademark Office connected therewith:

☒ Customer Number 22840

OR

☐ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☒ Customer Number or Bar Code Label 22840

OR ☐ Correspondence address below

Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle (if any))		Family Name or Surname			
Per-Olof		Larsson			
Inventor's Signature	x <i>[Signature]</i>			Date	Apr 1 2000
Residence: City	State	Country	Sweden	Citizenship	SE
Post Office Address	Fågelhundsvågen 56				
Post Office Address	S-226 53 Lund Sweden 3EX				
City	State	ZIP		Country	

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-87)  
Approved for use through 9/30/98. OMB 0551-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION

## ADDITIONAL INVENTOR(S) Supplemental Sheet

Page 1 of 1

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))

Family Name or Surname

Per-Erik

Gustavsson

Inventor's  
Signature

Per-Erik Gustavsson

Date

2001-04-20

Residence: City

State

Country

Sweden

Citizenship

SE

Post Office Address

Viklingavågen 11B

Post Office Address

S-224 76 Lund Sweden

SEX

City

State

ZIP

Country

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))

Family Name or Surname

Inventor's  
Signature

Date

Residence: City

State

Country

Citizenship

Post Office Address

Post Office Address

City

State

ZIP

Country

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))

Family Name or Surname

Inventor's  
Signature

Date

Residence: City

State

Country

Citizenship

Post Office Address

Post Office Address

City

State

ZIP

Country

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.